ReviewFrontiers in pharmacology2025
Gastrodin: a potential natural product for the prevention and treatment of cerebral ischemia-reperfusion injury.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Comparative Analysis of Extracellular Vesicle-Like Particles From Different ProcessingFood science & nutrition · 2026Article
- Gastrodin Ameliorates Type II Diabetes Through the YY1-FXR-Bile Acid Axis.International journal of molecular sciences · 2026Article
- Gastrodin improves learning and memory in sleep-deprived mice through suppression of ferroptosis in hippocampal neurons via Nrf2.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- [Gastrodin inhibits ferroptosis to alleviate hypoxic-ischemic brain damage in neonatal mice by activating GPX4/SLC7A11/FTH1 signaling].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2025Article
- Cerebral ischemia-reperfusion injury: mechanisms and promising therapies.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethnopharmacological relevance: Gastrodin is the main bioactive metabolite of Gastrodia elata Blume of traditional Chinese medicine, which has pharmacological effects such as anti-inflammatory, antioxidant, neuroprotective, vasoprotective, hypoglycemic, lipotropic, analgesic, anticancer, antiviral and so on, and it has been widely used in the treatment of a wide range of diseases, especially neurological disorders. Aim of the review: Cerebral ischemia-reperfusion injury (CIRI) is defined as transient or permanent ischemia of brain tissue that is further exacerbated by restoration of blood supply. Due to the complexity of the pathological processes of CIRI, current treatments have not shown the expected effects. More and more researchers are beginning to turn their focus on combating CIRI to natural metabolites derived from botanical drugs. This review provides an overview of the progress of research on the chemical composition, pharmacokinetics, safety, and pharmacological effects of Gastrodin in the treatment of CIRI. It aims to emphasize the important pharmacological effects and mechanisms of Gastrodin in the prevention and treatment of CIRI, and to provide reference for further drug research and development, as well as the future application of Gastrodin in CIRI. Materials and methods: A systematic literature search was conducted using keywords such as "Gastrodin," "traditional Chinese medicine," "chemical components," "metabolites," "cerebral ischemia-reperfusion injury," "CIRI," and "pharmacological effects" to identify relevant literature published from the establishment of the database to January 2025. Databases including PubMed, Web of Science, Google Scholar, and CNKI were utilized. Raw data were included in clinical trials and animal experiments. Other studies, such as reviews and systematic evaluations, were excluded. Results: GAS can prevent and treat cerebral ischemia/reperfusion-induced neurological injury by regulating a variety of molecular signals, exerting pharmacological effects such as anti-oxidative stress, inhibition of inflammatory response, inhibition of cell death, modulation of neurotransmitters, alleviation of neurotoxicity, promotion of neural repair, protection of the blood-brain barrier, and alleviation of cerebral edema, making it a potential natural metabolite for the effective treatment of CIRI. Conclusion: Gastrodin has significant value in the treatment of CIRI and there is extensive evidence to support its use in CIRI. Further research and clinical exploration of Gastrodin is necessary to fully utilize its therapeutic potential.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.